A paper published in the journal BioDrugs reported the results of a Phase III study conducted in Eastern Europe and...
Genentech and Partners File Motion to Dismiss their IPR Appeals Related to Genentech’s ACTEMRA® (Tocilizumab)
On February 12, 2024, Chugai, Genentech, and Hoffmann-La Roche filed a motion for voluntary dismissal of their appeals...
Takeda’s EOHILIA ® (budesonide oral suspension) Approved by FDA
Takeda announced it received approval for EOHILIA ® (budesonide oral suspension) for children aged 11 and older with...
Novartis’s Cosentyx® (secukinumab) Approved by Scottish Medicines Consortium (SMC) for Treatment of Active Moderate to Severe Hidradenitis Suppurativa (HS)
On 12 February 2024, SMC published that it has approved Novartis’s Cosentyx® (secukinumab) for treatment of active...
Health Canada Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Trastuzumab and Chemotherapy as Treatment for Adenocarcinoma Patients
On 12 February 2024, Merck announced that Health Canada approved its KEYTRUDA® (pembrolizumab) in combination with...
Biogen Receives European Commission’s Approval for SKYCLARYS® (omaveloxolone) to Treat Friedreich’s Ataxia
On 12 February 2024, Biogen announced that the European Commission approved its SKYCLARYS® (omaveloxolone) on 9...
Biocon Biologics Enter a Five-year Exclusive Partnership with Sandoz in Australia for Trastuzumab and Bevacizumab Biosimilars
On 9 February 2024, Biocon Biologics (Biocon) announced that it has signed a five-year exclusive partnership agreement...
Phase III Study Confirms Equivalence of Mabwell’s Denosumab Biosimilar with Amgen’s Xgeva®
A study sponsored by Mabwell (Shanghai) Bioscience Co Ltd and published in JAMA Oncology reports that the results of...
Dupilumab Study Shows Promising Results for Asthma Patients
A Sanofi and Regeneron study published on 11 December 2023 found that dupilumab (compared to placebo) significantly...
Samsung Biologics and LegoChem Biosciences Partner to Develop and Manufacture ADCs
On 7 February 2024, global contract development and manufacturing company Samsung Biologics announced that it has...
Celltrion to Supply Yuflyma® (adalimumab) and Remsima SC® (infliximab) to Norway
On 7 February 2024, the Korea IT Times reported that Celltrion announced that it has won the Norwegian government's...
FDA accepts BMS’ sBLA for Neoadjuvant Opdivo® (nivolumab)
On 7 February 2024, Bristol Myers Squibb (BMS) announced the FDA’s acceptance of its supplemental Biologics License...
Rani Therapeutics Releases Encouraging PhI Data for RT-111, Oral Form of Celltrion’s CT-P43 (ustekinumab) Biosimilar
On 5 February 2024, Rani Therapeutics published positive topline results from its phase I clinical trial regarding...
Novartis to Buy MorphoSys AG for €2.7B
On 5 February 2024, Novartis announced that it has agreed to acquire MorphoSys AG, a biopharmaceutical company focused...
GSK DREAMM-7 Phase III Trials Demonstrate Superior Results with Blenrep Combination
On 5 February 2024, Glaxo Smith Kline (GSK) announced results from an interim analysis of its DREAMM-7 phase III...
FDA Grants Fast Track Designation to Ultimovacs ASA’s UV1
On 5 February 2024, Ultimovacs announced that the FDA has granted a fast-track designation to its therapeutic cancer...